Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 60% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) compared to historical benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) overview

Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC is categorized into subtypes, primarily as carcinoma in situ (CIS), papillary tumors, and Ta/T1 tumors. CIS refers to flat, high-grade lesions that are confined to the mucosal surface, while papillary tumors grow as small, finger-like projections on the inner bladder lining. Ta tumors are limited to the innermost layer of the bladder lining, while T1 tumors have invaded into the connective tissue just beneath the lining but not into the muscle layer. This form of bladder cancer tends to recur despite treatment, making it a chronic condition that requires vigilant monitoring and periodic surveillance. However, it generally has a better prognosis than muscle-invasive bladder cancer.

For a complete picture of PTSR and LoA scores for drugs in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.